PLI-PHARMA

The scheme provides financial incentives on the incremental sales (over Base Year) of pharmaceutical goods and in-vitro diagnostic medical devices to selected applicants based on pre-defined selection criteria. The applicant must be a manufacturer of pharmaceutical goods.

The scheme "Production Linked Incentive (PLI) Scheme for Pharmaceuticals" was launched by the Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals. The scheme aims to enhance India’s manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. The scheme provides financial incentives on the incremental sales (over Base Year) of pharmaceutical goods and in-vitro diagnostic medical devices to selected applicants based on pre-defined selection criteria. The scheme is implemented by the Small Industries Development Bank of India. The applications for this scheme are accepted online through the dedicated Project Management Agency portal.

##### Common Eligibility

• The applicant must be a manufacturer of pharmaceutical goods registered in India.
• The applicant must be engaged in the manufacturing of eligible pharmaceutical products covered under the three defined categories.
• The applicant must not claim incentives for the same product under the Production Linked Incentive Scheme for Bulk Drugs or any other Production Linked Incentive Scheme.

##### Group A Applicants

• The applicant must have a Global Manufacturing Revenue of pharmaceutical goods or in-vitro Diagnostic Medical Devices greater than or equal to ₹50,00,00,00,000/- (₹5,000 crores) in the Financial Year 2019-20.
• The applicant must achieve a minimum cumulative investment of ₹10,00,00,00,000/- (₹1,000 crores) over a period of 5 years.
• The applicant must achieve a minimum turnover of eligible products of ₹50,00,00,000/- (₹50 crores) in the first year (Financial Year 2022-23).

##### Group B Applicants

• The applicant must have a Global Manufacturing Revenue of pharmaceutical goods or in-vitro Diagnostic Medical Devices between ₹5,00,00,00,000/- (₹500 crores) and ₹50,00,00,00,000/- (₹5,000 crores) in the Financial Year 2019-20.
• The applicant must achieve a minimum cumulative investment of ₹2,50,00,00,000/- (₹250 crores) over a period of 5 years.
• The applicant must achieve a minimum turnover of eligible products of ₹10,00,00,000/- (₹10 crores) in the first year (Financial Year 2022-23).

##### Group C Applicants

• The applicant must have a Global Manufacturing Revenue of pharmaceutical goods or in-vitro Diagnostic Medical Devices less than ₹5,00,00,00,000/- (₹500 crores) in the Financial Year 2019-20.
• The applicant must achieve a minimum cumulative investment of ₹50,00,00,000/- (₹50 crores) over a period of 5 years.
• The applicant must achieve a minimum turnover of eligible products of ₹1,00,00,000/- (₹1 crore) in the first year (Financial Year 2022-23).

##### Group C (MSME) Applicants

• The applicant must fall under the Micro, Small and Medium Enterprises (MSME) category within Group C.
• The applicant must achieve the Committed Investment (total eligible investment committed by the applicant) over a period of 5 years.
• The applicant must achieve a minimum turnover of eligible products of ₹50,00,000/- (₹50 lakhs) in the first year (Financial Year 2022-23).

##### Continuation Criteria

• The applicant must achieve a 7% growth in sales over the previous Financial Year for subsequent years (Financial Year 2023-24 onwards) to claim incentives.

• The scheme has a total financial outlay of ₹1,50,00,00,00,000/-.
• The incentive is provided on the net incremental sales of eligible products over a period of 6 years (Financial Year 2022-23 to Financial Year 2027-28).
• The rate of incentive for Category 1 and Category 2 products is 10% for the first four years (Financial Year 2022-23 to 2025-26), 8% for the fifth year (Financial Year 2026-27), and 6% for the sixth year (Financial Year 2027-28).
• The rate of incentive for Category 3 products is 5% for the first four years (Financial Year 2022-23 to 2025-26), 4% for the fifth year (Financial Year 2026-27), and 3% for the sixth year (Financial Year 2027-28).
• The incentive allocation ceiling is ₹1,10,00,00,00,000/- for Group A, ₹22,50,00,00,000/- for Group B, and ₹17,50,00,00,000/- for Group C.
• The maximum incentive per applicant is capped at ₹10,00,00,00,000/- for Group A, ₹2,50,00,00,000/- for Group B, and ₹50,00,00,000/- for Group C.

**Applicants must submit a claim for disbursement of incentive online on an annual basis within one month of the closure of the financial year.*

**75% of the claim amount is released immediately upon order, and the remaining 25% is released after the submission of final audited accounts.*

**Selected applicants must furnish a self-certified quarterly review report within 30 days from the end of each quarter.*